Travis Sifers, MD
Allergy & Immunology · Kansas City, MONPI 1922368539
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,500 of the $3,304 with a category attached, or 75.7%. ADMA Biomanufacturing LLC accounts for 97.0% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2024 at $3,239 and has fallen 99.5% since, to $17 in 2025.
Across 8 payments — averaging $412.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ADMA Biomanufacturing LLC$3K
- Pharming Healthcare, Inc.$51
- Pfizer$31
- Insmed, Inc.$17
Across 7 payments — averaging $2282.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Octapharma USA, Inc.$16K
What the payments were for
- Speaking & faculty fees$2,50076%
- Travel & lodging$65920%
- Food & beverage$963%
- Education$481%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ADMA Biomanufacturing LLC | 3 | $3,204 |
| Pharming Healthcare, Inc. | 2 | $51 |
| Pfizer | 2 | $31 |
| Insmed, Inc. | 1 | $17 |
How this compares
$3,304 in reported general payments places this provider in the 55th percentile of 61 allergy & immunology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 20 | $80,571 |
| Dupixent PenDupilumab | 13 | $46,273 |
| Dupixent SyringeDupilumab | 12 | $43,919 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $31,116 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $18,449 |
| Epinephrine | 41 | $6,740 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $5,100 |
| Wixela InhubFluticasone Propion/Salmeterol | 16 | $3,206 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 24 | $3,113 |
| Cromolyn Sodium | 17 | $3,090 |
| Pantoprazole Sodium | 138 | $2,308 |
| Ipratropium Bromide | 45 | $1,405 |
| Clobetasol Propionate | 11 | $618 |
| Azelastine Hcl | 17 | $476 |
| Methylprednisolone | 24 | $405 |
Paid to pharmacies, not to this prescriber.
Other allergy & immunology in Kansas City
- Lanny RosenwasserKansas City$46K
- Bridgette JonesKansas City$13K
- Haroon KhalidKansas City$7K
- Aarti PandyaKansas City$3K
- Neha PatelKansas City$1K
- Maggie BarnthouseKansas City$633
- Maya NandaKansas City$551
- Manali ShahKansas City$327
- Salman AljubranKansas City$125
- Zachary JacobsKansas City$33
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.